masteron enanthate

There are rare reports of the development syndrome (acute febrile dermatosis). Since many of these patients suffered from leukemia, which is known to be associated with masteron enanthate syndrome, a causal relationship with filgrastim has not been established.

In some cases, there is an exacerbation of rheumatoid arthritis.

Developing pseudogout reported in patients with cancer treated with filgrastim.

Rare undesirable effects in the lungs, including interstitial pneumonia, pulmonary edema and pulmonary infiltrates, and in rare cases with unfavorable outcome of respiratory failure or adult respiratory distress syndrome (ARDS), including fatalities have been reported.

Described isolated cases of occurrence of symptoms suggestive of allergic-type reactions, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea, reduced blood pressure, developing when administered the first dose or subsequent use of filgrastim, have been masteron enanthate reported in patients receiving filgrastim. Such reactions was greater following intravenous administration. In some cases, symptoms recurred after repeated use of filgrastim, which indicates a causal relationship. Application filgrastim should stop in patients who developed severe allergic reactions.

Isolated cases of sickle cell crises have been reported in patients with sickle cell anemia.

Immune system:
very rarely – allergic reactions.

On the part of metabolism and nutrition:
very often – increasing the activity , alkaline phosphatase, increase in the concentration of uric acid in the plasma.

From the nervous system:
often – headache.

On the part of the vessels:
Infrequent – increased permeability of capillaries syndrome; rarely -sosudistye violations angiopathy.

The respiratory system:
often -kashel, sore throat; very rarely masteron enanthate – pulmonary infiltrates.

From the gastrointestinal tract:
often – nausea, vomiting; often – constipation, diarrhea, anorexia, mucositis.

On the part of the liver and biliary tract:
often – increase of GGT activity.

Skin and subcutaneous tissue:
often – alopecia, skin rash; very rarely – Sweet’s syndrome, cutaneous vasculitis.

From the musculoskeletal system:
often – chest pain, musculoskeletal pain,
rarely – worsening of rheumatoid arthritis.

From the urinary system:
very rarely – a violation of masteron enanthate urination.

Other: often – fatigue, weakness; infrequently – nonspecific pain.